Resección hepática radioguiada con 18F-DOPA en un paciente con carcinoma medular de tiroides metastásico / Radioguided hepatic resection with 18F-DOPA in a patient with metastatic medullary thyroid carcinoma

Introducción: El carcinoma medular representa el 1-2% de todas las neoplasias tiroideas malignas. El 13-20% de los pacientes presenta metástasis a distancia, afectando al hígado en el 45% de los casos. Presentación de un caso: Una mujer de 50 años de edad, diagnosticada de carcinoma medular de tiroides, fue sometida a tiroidectomía total y disección cervical modificada en 1999. Se trataron con resección quirúrgica 2 recidivas ganglionares en el cuello; durante el periodo de vigilancia, la paciente desarrolló niveles elevados de calcitonina, identificándose la localización de la recidiva en el hígado mediante PET/TC con 18F-DOPA. La actividad metabólica no se asoció a lesión visible en TC, RM y ecografía. La cirugía radioguiada con 18F-DOPA permitió la resección anatómica de los segmentos IVb y V. Discusión: En pacientes con carcinoma medular y elevación de calcitonina durante el periodo de vigilancia, la PET/TC con 18F-DOPA es una opción para evaluar la localización de la recidiva. La resección radioguiada fue posible en esta paciente, cuya recidiva hepática no resultó visible con ningún otro método de imagen. Conclusión: La resección hepática radioguiada con 18F-DOPA en el carcinoma medular de tiroides metastásico es factible cuando la localización de la recidiva no puede identificarse anatómicamente mediante otros estudios de imagen

Introduction: Medullary carcinoma accounts for 1-2% of all thyroid malignancies. 13-20% of patients present with distant metastasis, with 45% of the cases affecting the liver. Clinical case: A 50-year-old woman, diagnosed with medullary thyroid carcinoma, was treated with total thyroidectomy and a modified neck dissection in 1999. Two lymph node recurrences in the neck were treated with surgical resection; during surveillance, she developed elevated calcitonin levels, the recurrence site was identified with 18F-DOPA PET/CT in the liver. Metabolic activity was not associated with a visible lesion in CT, MRI nor ultrasound. Radioguided surgery with 18F-DOPA allowed an anatomic resection of segments IVb and V. Discussion: In patients with medullary carcinoma and elevated calcitonin during surveillance, 18F-DOPA PET/CT is an option to evaluate the site of recurrence. Radioguided resection was feasible in this patient, whose hepatic recurrence was not visible with any other imaging method. Conclusion: Radioguided hepatic resection with 18F-DOPA in metastatic medullary thyroid carcinoma is feasible when the recurrence site is not anatomically identified by any other imaging studies

Radioguided hepatic resection with 18F-DOPA in a patient with metastatic medullary thyroid carcinoma. / Resección hepática radioguiada con 18F-DOPA en un paciente con carcinoma medular de tiroides metastásico.

INTRODUCTION: Medullary carcinoma accounts for 1-2% of all thyroid malignancies. 13-20% of patients present with distant metastasis, with 45% of the cases affecting the liver. CLINICAL CASE: A 50-year-old woman, diagnosed with medullary thyroid carcinoma, was treated with total thyroidectomy and a modified neck dissection in 1999. Two lymph node recurrences in the neck were treated with surgical resection; during surveillance, she developed elevated calcitonin levels, the recurrence site was identified with 18F-DOPA PET/CT in the liver. Metabolic activity was not associated with a visible lesion in CT, MRI nor ultrasound. Radioguided surgery with 18F-DOPA allowed an anatomic resection of segments IVb and V. DISCUSSION: In patients with medullary carcinoma and elevated calcitonin during surveillance, 18F-DOPA PET/CT is an option to evaluate the site of recurrence. Radioguided resection was feasible in this patient, whose hepatic recurrence was not visible with any other imaging method. CONCLUSION: Radioguided hepatic resection with 18F-DOPA in metastatic medullary thyroid carcinoma is feasible when the recurrence site is not anatomically identified by any other imaging studies.

Effectiveness of radiolabelled somatostatin analogues (90Y-DOTATOC and 177Lu-DOTATATE) in patients with metastatic neuroendocrine tumours: a single centre experience in Mexico. / Eficacia de los análogos de somatostatina radiomarcados (90Y-DOTATOC y 177Lu-DOTATATE) en pacientes con tumores neuroendocrinos metastásicos, experiencia de centro único en México.

OBJECTIVE: To determine the effectiveness of therapy with the radiolabelled somatostatin analogues, 90Y-DOTATOC and 177Lu-DOTATATE, in the treatment of metastatic neuroendocrine tumours with progression to first-line treatment. MATERIAL AND METHODS: A study was conducted on 30 patients diagnosed with neuroendocrine tumours (gastroenteropancreatic, bronchopulmonary, MEN2A, MEN2B, phaeochromocytoma, and paraganglioma) with metastatic disease diagnosed by the pathology department, with progression to first-line treatment, and recruited from December 2014 to February 2016. Efficacy was analysed using computed tomography (CT) according RECIST 1.1 criteria, and the molecular changes using the SUVmax of PET/CT with 68Ga-DOTATOC. Safety was carried out with a renal scan with 99mTc-MAG3. RESULTS: The 30 patients received a total of 49 cycles 90Y-DOTATOC (21 doses) and 177 Lu-DOTATATE (28 doses), with a mean of 1.5 cycles per patient. Of these, 17 (56.7%) showed a partial morphological response, 22 (73.3%) molecular and biochemical response, and 23 (76.6%) clinical response. One patient died during the median follow-up of 13 months. The median overall survival from diagnosis was 54 months (95% CI; 31.18-76.81), and median progression-free survival was 32 months (95% CI; 15.00-48.99). CONCLUSION: Therapy with 90Y-DOTATOC and 177Lu-DOTATATE is a promising therapy for patients with well and moderately differentiated neuroendocrine tumours. The efficacy is better the larger the number of cycles administered, inversely proportional to the number of metastases (<10), and is associated with the level of uptake according to the SUVmax by the metastases, regardless of metabolically active tumour volume.